Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Chemical Probe Targets Malignant Brain Tumor Genome

By LabMedica International staff writers
Posted on 14 Mar 2013
The development of a chemical probe that specifically targets the L3MBTL3 methyl-lysine reader domain will enable cancer researchers to investigate the function of malignant brain tumor (MBT) domain proteins in biology and disease.

L3MBTL3 (lethal(3)malignant brain tumor-like protein 3), which is required for normal maturation of myeloid progenitor cells, is a Polycomb group (PcG) protein. More...
PcG proteins are a family of proteins first discovered in fruit flies that can remodel chromatin so that epigenetic silencing of genes takes place. In humans Polycomb Group gene expression is important in many aspects of development. Mouse mutants lacking PRC2 (Polycomb Repressive Complex 2) genes die as embryos while most PRC1 (Polycomb Repressive Complex 1) mutants are born alive but with anatomic rearrangements that cause them to die shortly after birth. In contrast, overexpression of PcG proteins correlates with the severity and invasiveness of several cancer types.

A recent paper by investigators at the University of North Carolina (Chapel Hill, USA) described the use of the novel chemical probe UNC1215 for research on L3MBTL3. UNC1215 is a potent and selective chemical probe for the Kme reading function of L3MBTL3. Kme (methyl-lysine) recognition domains play a central role in epigenetic regulation during cellular differentiation, development, and gene transcription with more than 200 known “reader” domains in the human proteome. UNC1215 binds the MBT domains of L3MBTL3 and competitively displaces mono- or dimethyl-lysine containing peptides. This probe is greater than 50-fold more selective towards L3MBTL3 than towards other members of the human MBT family and also demonstrates selectivity against more than 200 other Kme reader domains.

Results obtained by X-ray crystallography published in the March 2013 issue of the journal Nature Chemical Biology revealed a unique 2:2 polyvalent mode of interaction between UNC1215 and L3MBTL3. In cells, UNC1215 was found to be nontoxic and bound to L3MBTL3 via the Kme-binding pocket of the MBT domains.

"Before this there were no known chemical probes for the more than 200 domains in the human genome that recognize methyl lysine. In that regard, it is a first in class compound. The goal is to use the chemical probe to understand the biology of the proteins that it targets," said first author Dr. Lindsey James, research assistant professor of chemical biology and medicinal chemistry at the University of North Carolina.

To promote research on the biology of malignant brain tumors the University of North Carolina will provide investigators with samples of UNC1215 free of charge on request.

Related Links:
University of North Carolina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.